Retro Bio raising $1bn to advance multiple longevity programs

Retro: A longevity biotech triple-threat?

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

Longevity biotech expects first clinical trial in autophagy this year, while advancing cellular programming and plasma-based therapies.

Hot on the heels of the news that it co-developed a new AI model for longevity science with OpenAI, Retro Biosciences is reportedly raising $1 billion to fuel the next stages of its development. According to the Financial Times, the longevity biotech, led by CEO Joe Betts-LaCroix, is also preparing to launch its first clinical trial this year.

Create a free account to read this article now

Join the 12,000+ biotech, pharma and investment leaders who read Longevity.Technology. No password, no payment.

By continuing you agree to our Terms and Privacy Policy, and to receive the free Longevity.Technology newsletter. You can unsubscribe at any time.

Danny Sullivan

Danny has worked in technology communications for more than 20 years, and has been writing about developments the longevity sector since 2019. With a keen interest in the transfer of technology to market, he focuses primarily on the companies working on cutting-edge solutions to aging and age-related diseases.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE